Acorda writes off another R&D program as Ampyra flops in stroke study
Six months after Acorda was forced to write off one of its drug candidates in the wake of a trial flop, the biotech is back with more bad news for investors. Its franchise drug Ampyra (dalfampridine) failed a pivotal study for helping stroke victims walk better. And Acorda is writing the effort off as a loser.
A little more than three years ago Acorda $ACOR was stoked by evidence of success in a small study of the same patient population. But an analysis of the data this time showed that the drug essentially lined up with a placebo when put to a major test.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
